Milestone Pharmaceuticals Inc

NASDAQ MIST

Data sourced from

and

Download Data

Milestone Pharmaceuticals Inc Revenue Per Share for the year ending December 31, 2023: USD 0.02

Milestone Pharmaceuticals Inc Revenue Per Share is USD 0.02 for the year ending December 31, 2023, a -80.24% change year over year. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors.

Milestone Pharmaceuticals Inc Revenue Per Share for the year ending December 31, 2022 was USD 0.12, a -67.15% change year over year.
Milestone Pharmaceuticals Inc Revenue Per Share for the year ending December 31, 2021 was USD 0.36, a -29.85% change year over year.
Milestone Pharmaceuticals Inc Revenue Per Share for the year ending December 31, 2020 was USD 0.51, a 0.00% change year over year.
Milestone Pharmaceuticals Inc Revenue Per Share for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.

NASDAQ: MIST

Milestone Pharmaceuticals Inc

CEO	Mr. Joseph G. Oliveto M.B.A.
IPO Date	May 9, 2019
Location	Canada
Headquarters	1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
Employees	47
Sector	Healthcare
Industry	Biotechnology

Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Key trends